Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Other Non Operating Income (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Other Non Operating Income for 7 consecutive years, with $273000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income rose 219.21% year-over-year to $273000.0, compared with a TTM value of -$539000.0 through Dec 2025, up 43.5%, and an annual FY2025 reading of -$539000.0, up 43.5% over the prior year.
  • Other Non Operating Income was $273000.0 for Q4 2025 at Keros Therapeutics, up from -$253000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $3.8 million in Q3 2023 and bottomed at -$1.4 million in Q4 2022.
  • Average Other Non Operating Income over 5 years is $60600.0, with a median of -$96500.0 recorded in 2021.
  • Peak annual rise in Other Non Operating Income hit 656.2% in 2022, while the deepest fall reached 1288.12% in 2022.
  • Year by year, Other Non Operating Income stood at -$101000.0 in 2021, then tumbled by 1288.12% to -$1.4 million in 2022, then soared by 103.99% to $56000.0 in 2023, then crashed by 508.93% to -$229000.0 in 2024, then soared by 219.21% to $273000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for KROS at $273000.0 in Q4 2025, -$253000.0 in Q3 2025, and -$221000.0 in Q2 2025.